Checkpoint Therapeutics (NASDAQ:CKPT) announced its quarterly earnings results on Friday. The company reported ($0.32) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.26) by ($0.06), MarketWatch Earnings reports. The company had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.26 million. Checkpoint Therapeutics had a negative net margin of 2,367.51% and a negative return on equity of 126.68%.
Shares of CKPT stock traded down $0.02 during mid-day trading on Friday, reaching $2.32. The company’s stock had a trading volume of 34,206 shares, compared to its average volume of 41,708. Checkpoint Therapeutics has a 12-month low of $2.04 and a 12-month high of $6.82.
A number of equities analysts have recently commented on CKPT shares. HC Wainwright set a $11.00 target price on shares of Checkpoint Therapeutics and gave the company a “buy” rating in a research note on Thursday, September 6th. ValuEngine raised shares of Checkpoint Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday. Finally, Zacks Investment Research downgraded shares of Checkpoint Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, October 9th.
Checkpoint Therapeutics Company Profile
Checkpoint Therapeutics, Inc, an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's products include CK-301 in Phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC); and CK-101 in the Phase 1 portion of a Phase 1/2 clinical trial for the treatment of epidermal growth factor receptor (EGFR) mutation-positive NSCLC.
Read More: Buyback For Investors Defined
Receive News & Ratings for Checkpoint Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.